Skip to content
ClinicalTrials.gov: newly registered trials· NYU Langone Health·· 18 days agoPickAI score60

NYU Langone registers trial of psilocybin-assisted psychotherapy for fear of cancer recurrence in early-stage breast cancer

Psilocybin FCR Early-Stage Breast Cancer

AI summary

NYU Langone Health has registered a , parallel-design, , two-centre of single-dose psilocybin-assisted psychotherapy in 100 outpatients with early-stage breast cancer. The trial is designed to evaluate efficacy and psychological mechanisms for fear of cancer recurrence (FCR), anxiety and depression distress and quality of life, comparing a single 25mg oral dose of psilocybin with a single 5mg oral dose as an active placebo, both delivered with a psychotherapy platform.

Why it matters

The registry record sets out a two-centre design with an active placebo, so readers can see how the trial plans to separate psilocybin from expectancy in fear of cancer recurrence.

Key facts

Compound
Psilocybin
Conditions
Depression, Anxiety
Jurisdiction
United States
Trial registration
NCT07909408 (ClinicalTrials.gov)
Source
ClinicalTrials.gov: newly registered trials (clinicaltrials.gov)
Published
How this summary was made

The summary and the “Why it matters” note were written by an AI model from the linked source, and a model scored the item against this site's editorial criteria. The facts above come from the item's topics and from identifiers written out in the stored text. Anything not found there is left out, so a missing row means not stated, not no. Read the original before relying on any detail. Editorial method

Source: ClinicalTrials.gov: newly registered trials · clinicaltrials.gov

Connected to

Compound
Psilocybin
Jurisdiction
United States

Other recent items on these topics